BROAD COVERAGE
Our Cell Microarray technology allows for screening against the most comprehensive set of expressed human membrane proteins currently available. We have >2000 human plasma membrane proteins represented (65% or all known), and are expanding to >2900 (95% of all known).
Furthermore, we are not limited to detecting binding at a single binding site (as with competition-based assays). Because our technology detects direct binding of drug to protein, we can discover important allosteric interactions.
RELEVANT
All proteins are human, full-length, non-fused and expressed in their native environment (i.e. in human cells). This allows for correct localisation and folding within the human plasma membrane. For antibody screening, no modifications to the test antibodies are required, since target binding is detected using a labelled secondary antibody. Other protein and peptide drugs can be screened using an appropriate tag. For small molecules, tritium labelling is preferred, as this avoids structural modifications to the drug which is a necessity for many other technologies.
Combined, these features ensure that all observed drug-protein interactions are relevant and avoid false negatives and positives common to other approaches.
SENSITIVE
Drug-protein interactions weaker than 0.1 µM are readily detected.
RAPID
At Retrogenix, we can fully profile a test compound in less than 4 weeks.
COST-EFFECTIVE
As well as offering a higher specification technology over competitor technologies, our solution is cost effective, and return on investment will be significant.
